Skip to main content
EVAX
NASDAQ Life Sciences

Evaxion to Present New Preclinical Data for AML Vaccine EVX-04 at EHA 2026, Plans H2 2026 CTA

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$4.3
Mkt Cap
$35.237M
52W Low
$1.48
52W High
$12.15
52W Position info
191% above low
Off High info
65% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

EVAX has more than doubled off its 52-week low of $1.48.

Summary

Evaxion announced it will present new preclinical data for its off-the-shelf AML vaccine candidate, EVX-04, at the EHA 2026 Congress and plans to submit a Clinical Trial Application in the second half of 2026.


Key Events · Product Development and Regulatory · EVAX

  • Preclinical Data Presentation for EVX-04

    Evaxion will present new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the European Hematology Association (EHA) 2026 Congress on June 13, 2026.

  • Clinical Trial Application Planned

    The company plans to submit a Clinical Trial Application (CTA) for EVX-04 in the second half of 2026, marking a step towards clinical testing.

  • AI-Immunology™ Platform Validation

    EVX-04 was developed using Evaxion's proprietary AI-Immunology™ platform, targeting non-conventional endogenous retrovirus (ERV) tumor antigens, demonstrating the platform's capability in identifying novel cancer targets.


Analysis · EVAX · Life Sciences

Evaxion is advancing its pipeline with new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia. The presentation at a major hematology congress and the stated plan to submit a Clinical Trial Application (CTA) in the second half of 2026 indicate progress towards clinical development for this candidate, which is significant for a clinical-stage biotech company.

How filings like this one have moved

In the 30 days to Nov 5, 2026, 33.4% of the 2397 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EVAX was trading at $4.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.2M. The 52-week trading range was $1.48 to $12.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EVAX - Latest Insights

EVAX
Oct 23, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.04
Real-time Price: $2.88 info
Change: -$1.16 (-29%) info
Market Cap: $24.77M info
EVAX
Oct 19, 2026, 3:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.25
Real-time Price: $2.88 info
Change: -$0.370 (-11%) info
Market Cap: $24.77M info
EVAX
Aug 20, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.47
Real-time Price: $2.88 info
Change: -$0.590 (-17%) info
Market Cap: $24.77M info
EVAX
Aug 20, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $3.48
Real-time Price: $2.88 info
Change: -$0.595 (-17%) info
Market Cap: $24.77M info
EVAX
Aug 17, 2026, 8:05 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.34
Real-time Price: $2.88 info
Change: -$0.460 (-14%) info
Market Cap: $24.77M info